Moderna 6 Year Stock Price History MRNA

what is moderna stock

© 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company’s weighted average against that of other companies.

  1. Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances.
  2. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams.
  3. As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.
  4. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.
  5. To see all exchange delays and terms of use please see Barchart’s disclaimer.

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company’s employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. The company issued 21,700,000 shares at a price https://www.wallstreetacademy.net/ of $22.00-$24.00 per share. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers. The stellar efficacy and safety profile of Moderna’s COVID-19 vaccine offered rapid validation of the firm’s mRNA technology.

Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More

The consensus among Wall Street research analysts is that investors should “hold” MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares. Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature’s DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

what is moderna stock

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

About Moderna Stock (NASDAQ:MRNA)

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. 15 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Moderna in the last twelve months. There are currently 2 sell ratings, 8 hold ratings and 5 buy ratings for the stock.

what is moderna stock

We’d like to share more about how we work and what drives our day-to-day business. Moderna’s Alexion partnership was terminated in 2017 after failure to find a safe but effective dose for the lead program, which could foreshadow difficulty finding a therapeutic window beyond low-dose vaccine programs. Upgrade to MarketBeat All Access to add more stocks to your watchlist. The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat’s FREE daily newsletter.

Moderna Earnings: Several Phase 3 Readouts and RSV Launch in 2024 Support Our Fair Value Estimate

Moderna issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $4.5 billion. Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Leave a Comment